bullish

Takeda: Nimbus Acquired Psoriasis Drug Showing Positive Results in Key Trial

256 Views20 Mar 2023 23:33
Takeda's psoriasis drug candidate acquired from Nimbus has shown positive results in key trials and has the potential to become superior to Bristol Myers' Sotyktu.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x